Manufacturer fuels Swiss biotech’s next-gen vaccine portfolio in new investment deal

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal designed to fuel the preclinical company’s R&D.

Related Posts

Praxis flouts phase 3 futility finding, forging ahead w...

Feb 28, 2025  0

AstraZeneca, eyeing $5B peak sales, reports phase 3 bre...

Feb 26, 2025  0

Paragonix's donor kidney perfusion system completes com...

Mar 3, 2025  0

Comments

Name

Email

Comment

Post Comment